In its first venture into the B-cell maturation antigen (BCMA) space, AbbVie has entered into a global agreement with Teneobio and its affiliate, TeneoOne, to develop and commercialise TNB-383B, a BCMA-targeting immunotherapeutic for the potential treatment of multiple myeloma. For US$90 M upfront, AbbVie has the option to acquire TeneoOne and lead developmental efforts after TeneoOne concludes Phase I studies. The deal comes less than a week after Gilead dropped its own anti-BCMA CAR-T therapy amid tough competition in the field.